AI Economy Reshapes Job Market BlueCollar Skilled Trades Gain as College EntryLevel Roles Slow Borosil Glass Works Surges Over 200 in a Year Whats Driving the Momentum Indian Equity Benchmarks Extend Gains for Third Session on Banking Financial and Auto Buying TikTok Goes Dark in US Market Uncertainty Looms as Trump Signals Potential Intervention Kevin Warshs Potential Fed Regime Change Could Reshape Wall Streets Market Plumbing Japanese Banks Spearhead Doubling of Global Infrastructure Funding Over Five Years BVN Q4 2025 Earnings Massive EPS Beat of 122 Driven by Strong Operational Performance CWEN Q1 2026 Earnings Significant EPS Miss Despite Positive Stock Movement FWONA Q4 2025 Earnings Narrow EPS Miss Amid Steady Formula One Operations STLA Q1 2026 Earnings EPS Misses Estimates Despite Stock Rally OMER Q1 2026 Earnings SmallerthanExpected Loss Amid No Revenue Stock Declines PCB Bancorp PCB Q1 2026 Earnings EPS Beats Estimates by 127 Amid Stable Operations Under Armour UA Gains Ground Testing Key Levels After 36 Surge Energy Focus Inc EFOI Edges Higher on Light Trading Key Levels in Focus Karman Holdings KRMN Holds Near Support After Modest Decline Ameriprise Financial AMP Edges Higher as Support Holds Resistance Ahead Hoth Therapeutics Soars Over 86 Volatile Session Pushes Key Technical Levels into Focus VNCE Q1 2026 Earnings Massive EPS Beat Surprises Market Despite Revenue Gap Crescent Capital BDC Inc CCAP Q1 2026 Earnings Slight Earnings Miss Amidst Stable Portfolio Performance EXPO Q1 2026 Earnings EPS Beats Estimates by 19 Amid Modest Revenue Headwinds PPL Q1 2026 Earnings EPS Beats Estimates Utility Operations Drive Steady Performance Valero Energy Q1 2026 Earnings Strong Refining Margins Drive 32 EPS Beat Despite Weaker Stock Reaction Heartflow Inc HTFL Q1 2026 Earnings EPS Miss Signals Margin Pressures Despite Modest Stock Gain Analysts Identify Potential Upside of Up to 40 in Key Sensex Stocks Including HDFC Bank ICICI Bank MM Cybin Inc HELP Q1 2026 Earnings WiderthanExpected Loss Highlights Clinical Development Costs Coherus Oncology CHRS Rises 37 as Stock Approaches Resistance at 178